LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Home・Akciju saraksts・Microbot Medical Inc

Microbot Medical Inc

Slēgts

2.48 2.9

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.26

Max

2.49

Galvenie mērījumi
By Trading Economics
Ienākumi	-77K -3.6M
Darbinieki	20
EBITDA	-79K -3.6M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+211.2% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 23. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-2.7M 138M
Iepriekšējā atvēršanas cena	-0.42
Iepriekšējā slēgšanas cena	2.48

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

2.52 / 2.57 Atbalsts un pretestība

Microbot Medical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. marts 23:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2026. g. 2. marts 23:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2026. g. 2. marts 23:26 UTC

Galvenie ziņu notikumi

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2026. g. 2. marts 22:41 UTC

Tirgus saruna

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2026. g. 2. marts 22:32 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 22:32 UTC

Tirgus saruna

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2026. g. 2. marts 22:21 UTC

Tirgus saruna

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2026. g. 2. marts 22:11 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 2. marts 22:11 UTC

Tirgus saruna

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2026. g. 2. marts 22:10 UTC

Iegādes, apvienošanās, pārņemšana

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2026. g. 2. marts 22:06 UTC

Tirgus saruna

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2026. g. 2. marts 22:00 UTC

Tirgus saruna

Peļņas

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 22:00 UTC

Tirgus saruna

Peļņas

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Energy & Utilities Roundup: Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 2. marts 21:35 UTC

Iegādes, apvienošanās, pārņemšana

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2026. g. 2. marts 21:34 UTC

Iegādes, apvienošanās, pārņemšana

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2026. g. 2. marts 21:30 UTC

Iegādes, apvienošanās, pārņemšana

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026. g. 2. marts 21:17 UTC

Galvenie ziņu notikumi

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2026. g. 2. marts 20:44 UTC

Peļņas

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026. g. 2. marts 20:43 UTC

Tirgus saruna

Galvenie ziņu notikumi

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2026. g. 2. marts 20:28 UTC

Peļņas

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2026. g. 2. marts 20:25 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2026. g. 2. marts 20:24 UTC

Peļņas

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026. g. 2. marts 20:14 UTC

Iegādes, apvienošanās, pārņemšana

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026. g. 2. marts 20:12 UTC

Galvenie ziņu notikumi

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2026. g. 2. marts 20:08 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 20:08 UTC

Tirgus saruna

Galvenie ziņu notikumi

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2026. g. 2. marts 20:05 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Salīdzinājums

Cenas izmaiņa

Microbot Medical Inc Prognoze

Cenas mērķis

By TipRanks

211.2% augšup

Prognoze 12 mēnešiem

Vidējais 7.5 USD 211.2%

Augstākais 12 USD

Zemākais 5 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

2.52 / 2.57Atbalsts un pretestība

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.